Drugmaker Novartis Launches Lottery for Access to Critical Spinal Muscular Atrophy Treatment
source: pixabay.com

Drugmaker Novartis Launches Lottery for Access to Critical Spinal Muscular Atrophy Treatment

According to a story from euronews.com, the drug maker Novartis has announced that it will give away its breakthrough spinal muscular atrophy gene therapy drug Zolgensma to 100 patients each…

Continue Reading Drugmaker Novartis Launches Lottery for Access to Critical Spinal Muscular Atrophy Treatment

FDA Grants Orphan Drug Designation to Cellectar’s CLR 131 for the Sixth Time

  The biopharmaceutical company Cellectar Biosciences recently announced that the FDA granted its lead phospholipid drug conjugate, CLR 131, Orphan Drug Designation(ODD) for treatment of lymphoplasmacytic lymphoma. ODD is granted by…

Continue Reading FDA Grants Orphan Drug Designation to Cellectar’s CLR 131 for the Sixth Time
New Therapies for LAM Disease and Facial Angiofibroma from AI Therapeutics
source: pixabay.com

New Therapies for LAM Disease and Facial Angiofibroma from AI Therapeutics

  AI Therapeutics is a biopharmaceutical company that has created an artificial intelligence platform that is meant to match drugs to new indications. This platform, called Guardian Angel, has matched…

Continue Reading New Therapies for LAM Disease and Facial Angiofibroma from AI Therapeutics
Experimental Drug Proves Superior to Eculizumab as a Treatment for Paroxysmal Nocturnal Hemoglobinuria
source: pixabay.com

Experimental Drug Proves Superior to Eculizumab as a Treatment for Paroxysmal Nocturnal Hemoglobinuria

According to a story from BioSpace, the biopharmaceutical company Apellis Pharmaceuticals, Inc., has recently announced the results of its phase 3 clinical trial, which was testing the company's investigational drug…

Continue Reading Experimental Drug Proves Superior to Eculizumab as a Treatment for Paroxysmal Nocturnal Hemoglobinuria
ICYMI: A New Year, a New Autoinflammatory Disease, and a Promising New Drug
source: pixabay.com

ICYMI: A New Year, a New Autoinflammatory Disease, and a Promising New Drug

  According to a recent article in Pharma Tutor, researchers at NHGRI, a division of the National Institute of Health, identified the biological cause of a newly-discovered autoinflammatory disease they named…

Continue Reading ICYMI: A New Year, a New Autoinflammatory Disease, and a Promising New Drug
A Biosimilar Drug for Treating Rheumatoid Arthritis and Ankylosing Spondylitis Begins Phase 3 Trials
source: pixabay.com

A Biosimilar Drug for Treating Rheumatoid Arthritis and Ankylosing Spondylitis Begins Phase 3 Trials

According to a story from Acrofan, the biotechnology company Clover Pharmaceuticals Inc. has recently announced that the first patient has been dosed in its phase 3 clinical study. This study…

Continue Reading A Biosimilar Drug for Treating Rheumatoid Arthritis and Ankylosing Spondylitis Begins Phase 3 Trials
A Polycystic Kidney Disease Patient’s Advertisement for a Kidney Donor Finds a Surprising Match
source: pixabay.com

A Polycystic Kidney Disease Patient’s Advertisement for a Kidney Donor Finds a Surprising Match

  By Rachel Whetstone from In The Cloud Copy Shelly Wheaton began a car sign campaign in September to look for a live kidney donor. She was on dialysis because…

Continue Reading A Polycystic Kidney Disease Patient’s Advertisement for a Kidney Donor Finds a Surprising Match